Diabetes PubMed

  • Increase font size
  • Default font size
  • Decrease font size
Home Complications Long Term Nerves Antinociceptive property of Emblica officinalis Gaertn (Amla) in high fat diet-fed/low dose streptozotocin induced diabetic neuropathy in rats

Antinociceptive property of Emblica officinalis Gaertn (Amla) in high fat diet-fed/low dose streptozotocin induced diabetic neuropathy in rats

Indian J Exp Biol. 2009 Sep;47(9):737-42.

Kumar NP, Annamalai AR, Thakur RS.

Department of Pharmacology, Krupanidhi College of Pharmacy, # 5, Sarjapur road, Koramangala, Bangalore 560 034, India. This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Erratum in: Indian J Exp Biol. 2009 Oct;47(10):778. Dosage error in article text.

Diabetic neuropathic pain is an important microvascular complication in diabetes mellitus and oxidative stress plays a vital role in associated neural and vascular complications. The present study investigated flavonoid rich fruit extract (ethyl acetate:methanol fraction) of E. officinalis (10 mg/kg), in type II diabetes (high fat diet fed/low dose streptozotocin) induced diabetic neuropathy in male Sprague-Dawley rats. Diabetic rats exhibited a significant hyperalgesia (nociception) as compared to control rats. Treatment with E. officinalis extract (EOE) and quercetin in diabetic rats showed significant increase in tail flick latency in hot immersion test and pain threshold level in hot plate test compared to control rats. The changes in lipid peroxidation status and anti-oxidant enzymes (superoxide dismutase and catalase) levels observed in diabetic rats were significantly restored by E. officinalis extract and quercetin treatment. Both, E. officinalis extract and quercetin attenuated diabetic induced axonal degeneration. The study provides experimental evidence of the preventive and curative effect of E. officinalis on nerve function and oxidative stress in animal model of diabetic neuropathy. Since, E. officinalis fruit is already in clinical use for diabetic patients it may be evaluated for preventive therapy in diabetic patients at risk of developing neuropathy.

PMID: 19957886

 

Bookmark and Share

Popular Diabetes PubMed Citations

Newsflash

Millions unite for diabetes awareness on World Diabetes Day 2010
Starting today, people from all corners of the world are uniting together for three days of celebration to put diabetes firmly in the public spotlight. World Diabetes Day is the best opportunity there is to draw attention to the silent killer that is diabetes.
 
Bristol-Myers Squibb Foundation Launches $100 Million Initiative
The Bristol-Myers Squibb Foundation announced Together on Diabetes®: Communities Uniting to Meet America's Diabetes Challenge, a 5-year, $100 million initiative to help patients living with type 2 diabetes better manage their disease beyond the doors of their doctor's office - in their homes and communities - and for the course of their disease.
 
New global survey reveals more than one in three patients fail to take insulin as prescribed
More than one in three diabetes patients skip doses or fail to take their insulin as prescribed, stating that they have done so on average three times in the last month, and 77% of physicians estimate that in reality this number could be as high as six doses*, according to the Global Attitudes of Patients and Physicians in Insulin Therapy (GAPPTM) survey, released today by Novo Nordisk.
 

Facebook Page Twitter Subscribe to Latest Diabetes PubMed facts... by Email RSS

Subscribe

Get Diabetes PubMed facts delivered by email. Enter your email address:


Delivered by FeedBurner

Who's Online

We have 3 guests online

Sponsored Links

PharmaNews.eu
PharmaNews.eu - the dynamic European pharmaceutical news engine.
www.pharmanews.eu

Advertise here